NSE: GLAXO | BSE: 500660

Expensive Performer

Download real time

2856.75 80.15 (2.89%)

55.09% Gain from 52W Low

175.7K NSE+BSE Volume

NSE 03 Apr, 2025 3:31 PM (IST)

48,395.1

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

GlaxoSmithKline Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAXO, BSE:500660 GlaxoSmithKline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Ltd.

26 Jul 2022

2856.75

2.89%

Pain and vaccine therapies hinder revenue growth???

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Pharmaceuticals Ltd. has gained 15.41% in the last 1 Month

GlaxoSmithKline Pharmaceuticals Ltd.

16 May 2022

2856.75

2.89%

Muted 4QFY22; focus remains on key brands to revitalize growth

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GlaxoSmithKline Pharmaceuticals Ltd. has gained 28.70% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

14 Mar 2022

2856.75

2.89%

GlaxcoSmithKline Pharmaceuticals Ltd- Report

Buy: GlaxoSmithKline Pharmaceut...

Joindre Capital Services

Number of FII/FPI investors increased from 337 to 347 in Dec 2024 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

07 Feb 2022

2856.75

2.89%

Product mix drives profitability

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GSK Pharma (GLXO) delivered in-line 3QFY22 earnings after including profits from discontinued operations. While the pharma portfolio tracked doubledigit growth, it was offset to some extent by the lower off-take of vaccines because of the third COVID wave. With COVID receding, we expect a gradual revival in the vaccine business. We have tweaked our EPS estimates for FY22/FY23/24 by 2% to factor in :a) an improved outlook for the vaccine business, b) a better traction in brands...

Number of FII/FPI investors increased from 337 to 347 in Dec 2024 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

30 Oct 2021

2856.75

2.89%

Favourable demand/Superior execution drives earnings growth

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GLXO's 2QFY22 performance was better than our expectations due to a healthy revival in the anti-infective/derma segment, coupled with improved operating leverage. In particular, Augmentin and Calpol regained their place among the top five brands in the Indian Pharmaceuticals Market (IPM). The...

GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

27 Jul 2021

2856.75

2.89%

Below expectations as margins disappoint; cut estimates 8 %/7 %

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

Revenue grew 22% YoY to INR7.9b (est. INR8.1b), led by Dermatology, AntiInfectives, and Pain/Analgesics segment. Gross margin expanded by 40bp YoY to 61.7% due to better product mix. EBITDA margin expanded at a higher rate (160bp YoY) to 19% (est. 21.5%) due to better operating leverage, with lower employee cost (down 220bp YoY as a percentage of sales), partially offset by higher other opex (+100bp...

GlaxoSmithKline Pharmaceuticals Ltd. has gained 44.96% in the last 1 Year

GlaxoSmithKline Pharmaceuticals Ltd.

19 May 2021

2856.75

2.89%

Dermatology outshines, while Anti-Infectives drags down 4Q

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GSK Pharma (GLXO)'s 4QFY21 performance was marginally below estimates, largely led by moderate YoY sales growth for the quarter. Based on AIOCD data, strong growth in the Dermatology segment was offset by a weak performance from the Anti-Infectives and Pain Analgesics segments. We raise our EPS estimates by 6%/7% for FY22E/FY23E, factoring in a) a robust outperformance from Dermatology, b) strong revival in AntiInfectives, Pain Analgesics, and Vitamins/Minerals/Nutrients, partly supported by the opportunity arising from COVID. We continue to value GLXO at 38x 12M forward earnings (25% discount to its three-year average)...

GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

07 Feb 2021

2856.75

2.89%

Better operating leverage drives profitability

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

GSK Pharma (GLXO)'s 3QFY21 performance was better than estimated, with an increase in sales driving higher profitability (on account of operating leverage). With the intensity of YoY decline lower over the past two quarters, GLXO exhibited low-double-digit YoY growth with the easing of the lockdown and partly aided by the low base of the past year. We increase our EPS estimates by 8%/3%/2% for FY21/FY22/FY23E, factoring in strong recovery in key therapies and improving productivity. We continue to value GLXO at 38x 12M forward earnings (25% discount to its...

Number of FII/FPI investors increased from 337 to 347 in Dec 2024 qtr.

GlaxoSmithKline Pharmaceuticals Ltd.

31 Jul 2020

2856.75

2.89%

GlaxoSmithKline Pharmaceuticals Ltd

Sell: GlaxoSmithKline Pharmaceut...

Target

Karvy

Outlook & Valuation: We downgrade our revenue estimates for FY21E / FY22E by 4.6% / 4.6% to Rs. 32.9 Bn / Rs. 36.3 Bn for FY21E / FY22E. We downgrade our EBITDA margins for FY21E / FY22E by 50 bps to 20.6%/21.9% due to fixed nature of personal cost.

GlaxoSmithKline Pharmaceuticals Ltd. is trading above all available SMAs

GlaxoSmithKline Pharmaceuticals Ltd.

29 Jul 2020

2856.75

2.89%

COVID-19-led weakness in performance

Neutral: GlaxoSmithKline Pharmaceut...

Target

Motilal Oswal

29 July 2020 GSK Pharma (GLXO)s performance for the quarter was deeply impacted by the COVID-19-led disruption. As a result, the company posted the lowest revenue recorded in the past 16 quarters. The severity amplified with reduced operating leverage. The outlook is expected to gradually improve with the easing of the lockdown. We reduce our EPS estimate by 26.3%/11.7% for FY21/FY22 to factor COVID- 19-led weakness in the Prescription and Vaccination segments. We continue to value GLXO at 37x 12M forward earnings (25% discount to its three-year average) to arrive at TP of INR1,355. GSK Pharma revenues were down 17.7% to INR6.5b (v/s est. GM expanded 230bp YoY to 60.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 44.96% in the last 1 Year

No results found

Is GlaxoSmithKline Pharmaceuticals Ltd. worth buying?

118 Votes:

Buy 65.25%

Sell 22.03%

Hold 12.71%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf